EUVIMEDEUVIMED entdecken
Crossref

Brain Metabolic Signatures of Amyloid‐ β and Tau Pathology in Corticobasal Syndrome: A Multimodal Biomarker Study

Xin-Yi Li, Jia-Ying Lu iD, Qi Shen, Yi-Xin Zhao, Kun-Wang Chan, Wen Liu, Jing-Jie Ge iD, Jue Zhao, Yi-Min Sun, Tzu-Chen Yen, Jian-Jun Wu, Chuan-Tao Zuo iD und 3 weitere

Movement Disorders · 2026

DOI: 10.1002/mds.70395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2026. Verfasst von Xin-Yi Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, National Clinical Research Center for Aging and Medicine, & National Center for Neurological Disorders, Huashan Hospital, Fu…. Hauptthemen laut MEDLINE: tau Proteins, Amyloid beta-Peptides, Corticobasal Degeneration, Brain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Brain Science and Brain-like Intelligence Technology-National Science and Technology Major Project, National Natural Science Foundation of China, Shanghai Municipal Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Corticobasal syndrome (CBS) may arise from heterogeneous neuropathological substrates, including corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Alzheimer's disease (AD), and biomarker‐based stratification has therefore become central to its characterization in vivo . In a large CBS cohort, we examined whether 18 F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) metabolic patterns reflect underlying amyloid‐ β deposition and tau topography, and how these patterns relate to the clinical phenotype.

Methods

We conducted a cross‐sectional study of consecutive patients with CBS and were enrolled at Huashan Hospital, Fudan University, between December 2019 and February 2025. Each patient underwent 18 F‐FDG PET for cerebral glucose metabolism, amyloid status assessment using amyloid PET or cerebrospinal fluid biomarkers, and florzolotau( 18 F) PET for tau topography.

Results

Among 113 patients, 18 F‐FDG PET identified five distinct metabolic subgroups: AD type (n = 20), CBD type I (n = 45), CBD type II (n = 18), PSP type (n = 26), and frontotemporal dementia type (n = 4). The AD metabolic pattern showed high specificity for amyloid‐ β positivity (98.5%) and for combined AD pathology (amyloid‐ β plus tau, 98.6%), with correspondingly lower sensitivity (54.2% and 72.2%). 18 F‐FDG PET patterns further showed high specificity for the PSP tau profile (96.2%) and high sensitivity for the CBD tau profile (97.7%). On spatial analysis, amyloid‐ β deposition significantly mediated the regional coupling between tau accumulation and cerebral glucose hypometabolism.

Conclusions

18 F‐FDG PET identifies metabolic patterns that correspond to specific proteinopathies underlying CBS with high specificity but requires integration within multimodal biomarker frameworks for comprehensive patient stratification. © 2026 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAmyloid beta-PeptidesCorticobasal DegenerationBrainHumansPositron-Emission TomographyFemaleBiomarkersCross-Sectional StudiesAgedMaleFluorodeoxyglucose F18Middle AgedAlzheimer DiseaseAged, 80 and over

Stichwörter der Autor:innen

18F‐FDG PETcorticobasal syndromeflorzolotau(18F) PETβ‐amyloid

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkersFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Neurology, National Clinical Research Center for Aging and Medicine, & National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, China.
  • Human Phenome Institute, Fudan University, Shanghai, China.

ORCID-Profile: Jia-Ying Lu, Jing-Jie Ge, Chuan-Tao Zuo, Jian Wang, Feng-Tao Liu

Förderung

  • Brain Science and Brain-like Intelligence Technology-National Science and Technology Major Project
  • National Natural Science Foundation of China
  • Shanghai Municipal Science and Technology Major Project
  • Clinical Research Project of Huashan Hospital, Fudan University
  • Huashan Hospital Seed Project
  • STI2030-Major Project
  • Shanghai Science and Technology Program Project
  • Shanghai Magnolia Talent Program Pujiang Project

Zitieren

APA

Li, X. Y., Lu, J. Y., Shen, Q., Zhao, Y. X., Chan, K. W., Liu, W., Ge, J. J., Zhao, J., Sun, Y. M., Yen, T. C., Wu, J. J., Zuo, C. T., Wang, J., Liu, F. T., & Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI) (2026). Brain Metabolic Signatures of Amyloid‐ β and Tau Pathology in Corticobasal Syndrome: A Multimodal Biomarker Study. Movement Disorders. https://doi.org/10.1002/mds.70395

Vancouver

Li XY, Lu JY, Shen Q, Zhao YX, Chan KW, Liu W, et al. Brain Metabolic Signatures of Amyloid‐ β and Tau Pathology in Corticobasal Syndrome: A Multimodal Biomarker Study. Movement Disorders. 2026. doi:10.1002/mds.70395

BibTeX
@article{Li2026,
  author = {Li, Xin-Yi and Lu, Jia-Ying and Shen, Qi and Zhao, Yi-Xin and Chan, Kun-Wang and Liu, Wen and Ge, Jing-Jie and Zhao, Jue and Sun, Yi-Min and Yen, Tzu-Chen and Wu, Jian-Jun and Zuo, Chuan-Tao and Wang, Jian and Liu, Feng-Tao and Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI), Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI)},
  title = {Brain Metabolic Signatures of Amyloid‐ β and Tau Pathology in Corticobasal Syndrome: A Multimodal Biomarker Study},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70395}
}
Kostenlos starten →